Advanced search
Publication Cover
Xenobiotica
the fate of foreign compounds in biological systems
Volume 28, 1998 - Issue 8
Submit an article Journal homepage
42
Views
26
CrossRef citations to date
0
Altmetric
Research Article

Effect of a new rifamycin derivative, rifalazil, on liver microsomal enzyme induction in rat and dog

T. MAE Takasago Research Laboratories, Research Institute, Kaneka Corp., 1-8, Miyamae-machi, Takasago-cho, Takasago-shi, Hyogo, 676-8688, Japan Covance Laboratories, Inc., PO Box 7545, Madison, WI 53707-7545, USA
,
K. HOSOE Takasago Research Laboratories, Research Institute, Kaneka Corp., 1-8, Miyamae-machi, Takasago-cho, Takasago-shi, Hyogo, 676-8688, Japan Covance Laboratories, Inc., PO Box 7545, Madison, WI 53707-7545, USA
,
T. YAMAMOTO Takasago Research Laboratories, Research Institute, Kaneka Corp., 1-8, Miyamae-machi, Takasago-cho, Takasago-shi, Hyogo, 676-8688, Japan Covance Laboratories, Inc., PO Box 7545, Madison, WI 53707-7545, USA
,
T. HIDAKA Takasago Research Laboratories, Research Institute, Kaneka Corp., 1-8, Miyamae-machi, Takasago-cho, Takasago-shi, Hyogo, 676-8688, Japan Covance Laboratories, Inc., PO Box 7545, Madison, WI 53707-7545, USA
,
T. OHASHI Takasago Research Laboratories, Research Institute, Kaneka Corp., 1-8, Miyamae-machi, Takasago-cho, Takasago-shi, Hyogo, 676-8688, Japan Covance Laboratories, Inc., PO Box 7545, Madison, WI 53707-7545, USA
,
J. M. KLEEMAN Takasago Research Laboratories, Research Institute, Kaneka Corp., 1-8, Miyamae-machi, Takasago-cho, Takasago-shi, Hyogo, 676-8688, Japan Covance Laboratories, Inc., PO Box 7545, Madison, WI 53707-7545, USA
&
P. E. ADAMS Takasago Research Laboratories, Research Institute, Kaneka Corp., 1-8, Miyamae-machi, Takasago-cho, Takasago-shi, Hyogo, 676-8688, Japan Covance Laboratories, Inc., PO Box 7545, Madison, WI 53707-7545, USA
 show all
Pages 759-766 | Published online: 22 Sep 2008

Citations (26)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (5)

Amina I Shehu, Guangming Li, Wen Xie & Xiaochao Ma. (2016) The pregnane X receptor in tuberculosis therapeutics. Expert Opinion on Drug Metabolism & Toxicology 12:1, pages 21-30.
Read now
David M Rothstein, Christo Shalish, Christopher K Murphy, Andrew Sternlicht & Lee Ann Campbell. (2006) Development potential of rifalazil and other benzoxazinorifamycins. Expert Opinion on Investigational Drugs 15:6, pages 603-623.
Read now
Hermann M. Bolt. (2004) Rifampicin, A Keystone Inducer of Drug Metabolism: From Herbert Remmer's Pioneering Ideas to Modern Concepts . Drug Metabolism Reviews 36:3-4, pages 497-509.
Read now
David M Rothstein, Arthur D Hartman, Michael H Cynamon & Barry I Eisenstein. (2003) Development potential of rifalazil. Expert Opinion on Investigational Drugs 12:2, pages 255-271.
Read now
T. Mae, T. Inaba, E. Konishi & K. Hosoe. (2000) Identification of enzymes responsible for rifalazil metabolism in human liver microsomes. Xenobiotica 30:6, pages 565-574.
Read now

Articles from other publishers (21)

Hanako Fukano, Kazue Nakanaga, Masamichi Goto, Mitsunori Yoshida, Norihisa Ishii & Yoshihiko Hoshino. (2022) Therapeutic efficacy of rifalazil (KRM-1648) in a M. ulcerans-induced Buruli ulcer mouse model. PLOS ONE 17:10, pages e0274742.
Crossref
Shireen R. Ashkar, Walajapet Rajeswaran, Pil H. Lee, Larisa Yeomans, Claire M. Thrasher, Scott G. Franzblau, Katsuhiko S. Murakami, Hollis D. Showalter & George A. Garcia. (2022) Optimization of Benzoxazinorifamycins to Minimize hPXR Activation for the Treatment of Tuberculosis and HIV Coinfection. ACS Infectious Diseases 8:8, pages 1408-1421.
Crossref
Adila Nazli, David L. He, Huacheng Xu, Zhi-Peng Wang & Yun He. (2022) A Comparative Insight on the Newly Emerging Rifamycins: Rifametane, Rifalazil, TNP-2092 and TNP-2198. Current Medicinal Chemistry 29:16, pages 2846-2862.
Crossref
Hamed Mosaei & Nikolay Zenkin. (2020) Inhibition of RNA Polymerase by Rifampicin and Rifamycin-Like Molecules. EcoSal Plus 9:1.
Crossref
Chrissy M. Leopold Wager, Eusondia Arnett & Larry S. Schlesinger. (2019) Mycobacterium tuberculosis and macrophage nuclear receptors: What we do and don't know. Tuberculosis 116, pages S98-S106.
Crossref
Tamara Staudinger, Bernhard Redl & Ben J. Glasgow. (2014) Antibacterial activity of rifamycins for M. smegmatis with comparison of oxidation and binding to tear lipocalin. Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics 1844:4, pages 750-758.
Crossref
Vadim Molodtsov, Irosha N. Nawarathne, Nathan T. Scharf, Paul D. Kirchhoff, H. D. Hollis Showalter, George A. Garcia & Katsuhiko S. Murakami. (2013) X-ray Crystal Structures of the Escherichia coli RNA Polymerase in Complex with Benzoxazinorifamycins . Journal of Medicinal Chemistry 56:11, pages 4758-4763.
Crossref
Sumandeep K. Gill, Hao Xu, Paul D. Kirchhoff, Tomasz Cierpicki, Anjanette J. Turbiak, Baojie Wan, Nan Zhang, Kuan-Wei Peng, Scott G. Franzblau, George A. Garcia & H. D. Hollis Showalter. (2012) Structure-Based Design of Novel Benzoxazinorifamycins with Potent Binding Affinity to Wild-Type and Rifampin-Resistant Mutant Mycobacterium tuberculosis RNA Polymerases . Journal of Medicinal Chemistry 55:8, pages 3814-3826.
Crossref
Paul A. Aristoff, George A. Garcia, Paul D. Kirchhoff & H.D. Hollis Showalter. (2010) Rifamycins – Obstacles and opportunities. Tuberculosis 90:2, pages 94-118.
Crossref
DAVID P. CALFEE. 2010. Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases. Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases 403 417 .
Kevin W Garey, Miguel Salazar, Dhara Shah, Richard Rodrigue & Herbert L DuPont. (2008) Rifamycin Antibiotics for Treatment of Clostridium difficile–Associated Diarrhea. Annals of Pharmacotherapy 42:6, pages 827-835.
Crossref
James C. Sacchettini, Eric J. Rubin & Joel S. Freundlich. (2008) Drugs versus bugs: in pursuit of the persistent predator Mycobacterium tuberculosis. Nature Reviews Microbiology 6:1, pages 41-52.
Crossref
Marita Larsson, Arthur F. Michaelis, Yongdong Zhu & Kumar Ramu. (2007) Determination of rifalazil, a potent antibacterial agent, in human plasma by liquid–liquid extraction and LC–MS/MS. Journal of Chromatography B 859:1, pages 103-110.
Crossref
David M. Rothstein, John van Duzer, Andrew Sternlicht & Steven C. Gilman. (2007) Rifalazil and Other Benzoxazinorifamycins in the Treatment of Chlamydia‐Based Persistent Infections. Archiv der Pharmazie 340:10, pages 517-529.
Crossref
Y.‐X. Chen, B. Cabana, N. Kivel & A. Michaelis. (2013) Effect of Food on the Pharmacokinetics of Rifalazil, a Novel Antibacterial, in Healthy Male Volunteers. The Journal of Clinical Pharmacology 47:7, pages 841-849.
Crossref
Minsheng Xia, Robert J. Suchland, Joli A. Carswell, John Van Duzer, Debra K. Buxton, Kara Brown, David M. Rothstein & Walter E. Stamm. (2005) Activities of Rifamycin Derivatives against Wild-Type and rpoB Mutants of Chlamydia trachomatis . Antimicrobial Agents and Chemotherapy 49:9, pages 3974-3976.
Crossref
Richard J. O'Brien & Mel Spigelman. (2005) New Drugs for Tuberculosis: Current Status and Future Prospects. Clinics in Chest Medicine 26:2, pages 327-340.
Crossref
Masashi Mise, Seiji Yadera, Michiaki Matsuda, Takanori Hashizume, Satoshi Matsumoto, Yoshiaki Terauchi & Toshihiko Fujii. (2004) POLYMORPHIC EXPRESSION OF CYP1A2 LEADING TO INTERINDIVIDUAL VARIABILITY IN METABOLISM OF A NOVEL BENZODIAZEPINE RECEPTOR PARTIAL INVERSE AGONIST IN DOGS. Drug Metabolism and Disposition 32:2, pages 240-245.
Crossref
Richard A. Graham, April Downey, Dan Mudra, Linda Krueger, Kathy Carroll, Christopher Chengelis, Ajay Madan & Andrew Parkinson. (2002) In Vivo and in Vitro Induction of Cytochrome P450 Enzymes in Beagle Dogs. Drug Metabolism and Disposition 30:11, pages 1206-1213.
Crossref
Reynaldo DietzeLuciléia TeixeiraLia Márcia Canedo RochaMoisés PalaciJohn L. JohnsonCharles Wells, Lynn Rose, Kathleen Eisenach & Jerrold J. Ellner. (2001) Safety and Bactericidal Activity of Rifalazil in Patients with Pulmonary Tuberculosis. Antimicrobial Agents and Chemotherapy 45:7, pages 1972-1976.
Crossref
Charles A. Peloquin. 2001. Drug Interactions in Infectious Diseases. Drug Interactions in Infectious Diseases 109 120 .

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.